| Ticker | Status | Jurisdiction | Filing Date | CP Start | CP End | CP Loss | Deadline |
|---|
| Ticker | Case Name | Status | CP Start | CP End | Deadline | Settlement Amt |
|---|
| Ticker | Name | Date | Analyst Firm | Up/Down | Target ($) | Rating Change | Rating Current |
|---|
Throughout the last three months, 8 analysts have evaluated Hims & Hers Health (NYSE:HIMS), offering a diverse set of opinions from bullish to bearish.
The table below summarizes their recent ratings, showcasing the evolving sentiments within the past 30 days and comparing them to the preceding months.
| Bullish | Somewhat Bullish | Indifferent | Somewhat Bearish | Bearish | |
|---|---|---|---|---|---|
| Total Ratings | 4 | 0 | 4 | 0 | 0 |
| Last 30D | 1 | 0 | 0 | 0 | 0 |
| 1M Ago | 2 | 0 | 1 | 0 | 0 |
| 2M Ago | 0 | 0 | 3 | 0 | 0 |
| 3M Ago | 1 | 0 | 0 | 0 | 0 |
Analysts have recently evaluated Hims & Hers Health and provided 12-month price targets. The average target is $19.5, accompanied by a high estimate of $26.00 and a low estimate of $13.00. Observing a 16.42% increase, the current average has risen from the previous average price target of $16.75.
A comprehensive examination of how financial experts perceive Hims & Hers Health is derived from recent analyst actions. The following is a detailed summary of key analysts, their recent evaluations, and adjustments to ratings and price targets.
| Analyst | Analyst Firm | Action Taken | Rating | Current Price Target | Prior Price Target |
|---|---|---|---|---|---|
| Michael Cherny | B of A Securities | Raises | Buy | $26.00 | $22.00 |
| Michael Cherny | B of A Securities | Raises | Buy | $22.00 | $17.25 |
| Maria Ripps | Canaccord Genuity | Raises | Buy | $24.00 | $20.00 |
| Daniel Grosslight | Citigroup | Raises | Neutral | $20.00 | $16.00 |
| George Hill | Deutsche Bank | Raises | Hold | $16.00 | $14.00 |
| Korinne Wolfmeyer | Piper Sandler | Raises | Neutral | $13.00 | $11.00 |
| Glen Santangelo | Jefferies | Lowers | Hold | $15.00 | $17.00 |
| Maria Ripps | Canaccord Genuity | Announces | Buy | $20.00 | - |
Analyzing these analyst evaluations alongside relevant financial metrics can provide a comprehensive view of Hims & Hers Health's market position. Stay informed and make data-driven decisions with the assistance of our Ratings Table.
Stay up to date on Hims & Hers Health analyst ratings.
Hims & Hers Health Inc is a multi-specialty telehealth platform that connects consumers to licensed healthcare professionals, enabling them to access high-quality medical care for numerous conditions related to mental health, sexual health, dermatology, primary care, and more.
Market Capitalization Analysis: The company's market capitalization is below the industry average, suggesting that it is relatively smaller compared to peers. This could be due to various factors, including perceived growth potential or operational scale.
Positive Revenue Trend: Examining Hims & Hers Health's financials over 3 months reveals a positive narrative. The company achieved a noteworthy revenue growth rate of 45.81% as of 31 March, 2024, showcasing a substantial increase in top-line earnings. As compared to competitors, the company surpassed expectations with a growth rate higher than the average among peers in the Health Care sector.
Net Margin: Hims & Hers Health's net margin is impressive, surpassing industry averages. With a net margin of 4.0%, the company demonstrates strong profitability and effective cost management.
Return on Equity (ROE): Hims & Hers Health's ROE excels beyond industry benchmarks, reaching 3.23%. This signifies robust financial management and efficient use of shareholder equity capital.
Return on Assets (ROA): Hims & Hers Health's financial strength is reflected in its exceptional ROA, which exceeds industry averages. With a remarkable ROA of 2.5%, the company showcases efficient use of assets and strong financial health.
Debt Management: The company maintains a balanced debt approach with a debt-to-equity ratio below industry norms, standing at 0.03.
Analyst ratings serve as essential indicators of stock performance, provided by experts in banking and financial systems. These specialists diligently analyze company financial statements, participate in conference calls, and engage with insiders to generate quarterly ratings for individual stocks.
Beyond their standard evaluations, some analysts contribute predictions for metrics like growth estimates, earnings, and revenue, furnishing investors with additional guidance. Users of analyst ratings should be mindful that this specialized advice is shaped by human perspectives and may be subject to variability.
This article was generated by Benzinga's automated content engine and reviewed by an editor.
Posted In: HIMS
